文献速递糖尿病

胎球蛋白A干扰胰岛β细胞功能成熟

The hepatokine fetuin-A disrupts functional maturation of pancreatic beta cells.
PubMed 文献 · Diabetologia · 2021-03-25

该研究在猪新生儿胰岛细胞簇与成人胰岛中观察胎球蛋白A对β细胞功能成熟的影响。胎球蛋白A抑制β细胞标志基因上调与葡萄糖反应性出现,并抑制增殖;在非糖尿病人群中血浆胎球蛋白A与胰岛β细胞面积负相关。

要点

  • 胎球蛋白A抑制新生儿β细胞功能成熟及葡萄糖反应性出现
  • 胎球蛋白A抑制β细胞增殖并减少胰岛素阳性细胞数量
  • 血浆胎球蛋白A与胰岛β细胞面积呈负相关

核心结论

  • 胎球蛋白A围产期下降可解除胰岛TGFBR信号,促进新生儿β细胞功能成熟。
  • 成年期功能成熟可逆转,肝脏脂肪变性与血浆胎球蛋白A升高可损害β细胞功能与适应性增殖。

研究设计与样本

  • 体外研究:猪新生儿胰岛细胞簇(NICCs)成熟过程与成人胰岛。
  • 检测方法包括微阵列、RNA测序、qRT-PCR、western blotting、免疫染色与静态孵育胰岛素分泌。
  • 非糖尿病人群中分析血浆胎球蛋白A与胰岛β细胞面积的相关性。

主要发现

  • NICC成熟伴随葡萄糖反应性胰岛素分泌增加(twofold stimulation)及NEUROD1、UCN3、ABCC8、CASR上调(Log2FC > 1.6)。
  • TGFBR抑制剂SB431542抵消上述基因上调并去抑制ALDOB。
  • 胎球蛋白A处理抑制β细胞标志物上调与葡萄糖反应性出现,并抑制SMAD2/3磷酸化。
  • 胎球蛋白A抑制β细胞增殖(0.27 ± 0.08% vs 1.0 ± 0.1% Ki67阳性细胞),FOXM1、CENPA、CDK1、TOP2A表达降低(Log2FC ≤ -2.4)。
  • 胎球蛋白A处理NICC中胰岛素阳性细胞比例低于对照(14.4 ± 1.2% vs 22.3 ± 1.1%)。

临床怎么用

  • 围产期胎球蛋白A下降可能作为β细胞功能成熟的生理信号。
  • 肝脏脂肪变性相关胎球蛋白A升高可能损害β细胞功能与适应性增殖。
  • 血浆胎球蛋白A或可作为β细胞面积减少的关联指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Neonatal beta cells carry out a programme of postnatal functional maturation to achieve full glucose responsiveness. A partial loss of the mature phenotype of adult beta cells may contribute to a reduction of functional beta cell mass and accelerate the onset of type 2 diabetes. We previously found that fetuin-A, a hepatokine increasingly secreted by the fatty liver and a determinant of type 2 diabetes, inhibits glucose-stimulated insulin secretion (GSIS) of human islets. Since fetuin-A is a ubiquitous fetal glycoprotein that declines peripartum, we examined here whether fetuin-A interferes with the functional maturity of beta cells. METHODS: The effects of fetuin-A were assessed during in vitro maturation of porcine neonatal islet cell clusters (NICCs) and in adult human islets. Expression alterations were examined via microarray, RNA sequencing and reverse transcription quantitative real-time PCR (qRT-PCR), proteins were analysed by western blotting and immunostaining, and insulin secretion was quantified in static incubations. RESULTS: NICC maturation was accompanied by the gain of glucose-responsive insulin secretion (twofold stimulation), backed up by mRNA upregulation of genes governing beta cell identity and function, such as NEUROD1, UCN3, ABCC8 and CASR (Log2 fold change [Log2FC] > 1.6). An active TGFβ receptor (TGFBR)-SMAD2/3 pathway facilitates NICC maturation, since the TGFBR inhibitor SB431542 counteracted the upregulation of aforementioned genes and de-repressed ALDOB, a gene disallowed in mature beta cells. In fetuin-A-treated NICCs, upregulation of beta cell markers and the onset of glucose responsiveness were suppressed. Concomitantly, SMAD2/3 phosphorylation was inhibited. Transcriptome analysis confirmed inhibitory effects of fetuin-A and SB431542 on TGFβ-1- and SMAD2/3-regulated transcription. However, contrary to SB431542 and regardless of cMYC upregulation, fetuin-A inhibited beta cell proliferation (0.27 ± 0.08% vs 1.0 ± 0.1% Ki67-positive cells in control NICCs). This effect was sustained by reduced expression (Log2FC ≤ -2.4) of FOXM1, CENPA, CDK1 or TOP2A. In agreement, the number of insulin-positive cells was lower in fetuin-A-treated NICCs than in control NICCs (14.4 ± 1.2% and 22.3 ± 1.1%, respectively). In adult human islets fetuin-A abolished glucose responsiveness, i.e. 1.7- and 1.1-fold change over 2.8 mmol/l glucose in control- and fetuin-A-cultured islets, respectively. In addition, fetuin-A reduced SMAD2/3 phosphorylation and suppressed expression of proliferative genes. Of note, in non-diabetic humans, plasma fetuin-A was negatively correlated (p = 0.013) with islet beta cell area. CONCLUSIONS/INTERPRETATION: Our results suggest that the perinatal decline of fetuin-A relieves TGFBR signalling in islets, a process that facilitates functional maturation of neonatal beta cells. Functional maturity remains revocable in later life, and the occurrence of a metabolically unhealthy milieu, such as liver steatosis and elevated plasma fetuin-A, can impair both function and adaptive proliferation of beta cells. DATA AVAILABILITY: The RNAseq datasets and computer code produced in this study are available in the Gene Expression Omnibus (GEO): GSE144950; https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE144950.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Gerst F, Kemter E, Lorza-Gil E, et al. The hepatokine fetuin-A disrupts functional maturation of pancreatic beta cells. Diabetologia. 2021. PMID: 33765181. doi:10.1007/s00125-021-05435-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。